Aug 1 |
Arbutus: Q2 Earnings Snapshot
|
Aug 1 |
Arbutus Biopharma GAAP EPS of -$0.11 misses by $0.01, revenue of $1.73M misses by $0.03M
|
Aug 1 |
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Jul 31 |
Arbutus Biopharma Q2 2024 Earnings Preview
|
Jul 23 |
Amgen, Garmin among relative market leaders poised to outperform in coming months: BTIG
|
Jul 18 |
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
|
Jul 5 |
Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard'
|
Jul 5 |
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
|
Jun 13 |
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
|
Jun 6 |
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
|